Search

Your search keyword '"Dachuan Huang"' showing total 115 results
Start Over Author "Dachuan Huang"
115 results on '"Dachuan Huang"'

1. Single‐Cell Analysis Reveals Malignant Cells Reshape the Cellular Landscape and Foster an Immunosuppressive Microenvironment of Extranodal NK/T‐Cell Lymphoma

Author

Yi‐Qi Li, Chun‐Ling Luo, Jia‐Xin Jiang, Shuai He, Yang Liu, Wen‐Xin Yan, Yi Xia, Qian Cui, Ying Huang, Jing Quan Lim, Dachuan Huang, Izzah Nabilah Hussein, Yan Gao, Guo‐Wang Lin, Yi‐Hong Ling, Dong Ma, Yue‐Tong Zhang, Jason Yongsheng Chan, Pan‐Pan Wei, Xiao‐Xiao Wang, Chee Leong Cheng, Jie Xiong, Wei‐Li Zhao, Choon Kiat Ong, Soon Thye Lim, Hui‐Qiang Huang, Rou‐Jun Peng, and Jin‐Xin Bei

Subjects
DPP4, immunosuppression, LMP1+ malignant NK cells, NKTCL, scRNA‐seq, Science
Abstract

Abstract Extranodal natural killer/T‐cell lymphoma (NKTCL) is an aggressive type of lymphoma associated with Epstein–Barr virus (EBV) and characterized by heterogeneous tumor behaviors. To better understand the origins of the heterogeneity, this study utilizes single‐cell RNA sequencing (scRNA‐seq) analysis to profile the tumor microenvironment (TME) of NKTCL at the single‐cell level. Together with in vitro and in vivo models, the study identifies a subset of LMP1+ malignant NK cells contributing to the tumorigenesis and development of heterogeneous malignant cells in NKTCL. Furthermore, malignant NK cells interact with various immunocytes via chemokines and their receptors, secrete substantial DPP4 that impairs the chemotaxis of immunocytes and regulates their infiltration. They also exhibit an immunosuppressive effect on T cells, which is further boosted by LMP1. Moreover, high transcription of EBV‐encoded genes and low infiltration of tumor‐associated macrophages (TAMs) are favorable prognostic indicators for NKTCL in multiple patient cohorts. This study for the first time deciphers the heterogeneous composition of NKTCL TME at single‐cell resolution, highlighting the crucial role of malignant NK cells with EBV‐encoded LMP1 in reshaping the cellular landscape and fostering an immunosuppressive microenvironment. These findings provide insights into understanding the pathogenic mechanisms of NKTCL and developing novel therapeutic strategies against NKTCL.

Published
2023
Full Text
View/download PDF

2. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide

Author

Jinghong Chen, Zhixiang Zuo, Yan Gao, Xiaosai Yao, Peiyong Guan, Yali Wang, Zhimei Li, Zhilong Liu, Jing Han Hong, Peng Deng, Jason Yongsheng Chan, Daryl Ming Zhe Cheah, Jingquan Lim, Kelila Xin Ye Chai, Burton Kuan Hui Chia, Jane Wan Lu Pang, Joanna Koh, Dachuan Huang, Haixia He, Yichen Sun, Lizhen Liu, Shini Liu, Yuhua Huang, Xiaoxiao Wang, Hua You, Sahil Ajit Saraf, Nicholas Francis Grigoropoulos, Xiaoqiu Li, Jinxin Bei, Tiebang Kang, Soon Thye Lim, Bin Tean Teh, Huiqiang Huang, Choon Kiat Ong, and Jing Tan

Subjects
NKTL, HDAC inhibitor, Chidamide resistance, JAK-STAT pathway, Chromatin remodeling, Medicine, Genetics, QH426-470
Abstract

Abstract Background Natural killer/T-cell lymphoma (NKTL) is a rare type of aggressive and heterogeneous non-Hodgkin's lymphoma (NHL) with a poor prognosis and limited therapeutic options. Therefore, there is an urgent need to exploit potential novel therapeutic targets for the treatment of NKTL. Histone deacetylase (HDAC) inhibitor chidamide was recently approved for treating relapsed/refractory peripheral T-cell lymphoma (PTCL) patients. However, its therapeutic efficacy in NKTL remains unclear. Methods We performed a phase II clinical trial to evaluate the efficacy of chidamide in 28 relapsed/refractory NKTL patients. Integrative transcriptomic, chromatin profiling analysis and functional studies were performed to identify potential predictive biomarkers and unravel the mechanisms of resistance to chidamide. Immunohistochemistry (IHC) was used to validate the predictive biomarkers in tumors from the clinical trial. Results We demonstrated that chidamide is effective in treating relapsed/refractory NKTL patients, achieving an overall response and complete response rate of 39 and 18%, respectively. In vitro studies showed that hyperactivity of JAK-STAT signaling in NKTL cell lines was associated with the resistance to chidamide. Mechanistically, our results revealed that aberrant JAK-STAT signaling remodels the chromatin and confers resistance to chidamide. Subsequently, inhibition of JAK-STAT activity could overcome resistance to chidamide by reprogramming the chromatin from a resistant to sensitive state, leading to synergistic anti-tumor effect in vitro and in vivo. More importantly, our clinical data demonstrated that combinatorial therapy with chidamide and JAK inhibitor ruxolitinib is effective against chidamide-resistant NKTL. In addition, we identified TNFRSF8 (CD30), a downstream target of the JAK-STAT pathway, as a potential biomarker that could predict NKTL sensitivity to chidamide. Conclusions Our study suggests that chidamide, in combination with JAK-STAT inhibitors, can be a novel targeted therapy in the standard of care for NKTL. Trial registration: ClinicalTrials.gov, NCT02878278. Registered 25 August 2016, https://clinicaltrials.gov/ct2/show/NCT02878278

Published
2023
Full Text
View/download PDF

3. Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma

Author

Daniel Ren Yi Yap, Jing Quan Lim, Dachuan Huang, Choon Kiat Ong, and Jason Yongsheng Chan

Subjects
tumor microenvironment, genomics, checkpoint immunotherapy, precision oncology, targeted therapy, Immunologic diseases. Allergy, RC581-607
Abstract

Peripheral T-cell lymphoma (PTCL) and natural killer/T-cell lymphoma (NKTCL) are rare subtypes of non-Hodgkin’s lymphoma that are typically associated with poor treatment outcomes. Contemporary first-line treatment strategies generally involve the use of combination chemoimmunotherapy, radiation and/or stem cell transplant. Salvage options incorporate a number of novel agents including epigenetic therapies (e.g. HDAC inhibitors, DNMT inhibitors) as well as immune checkpoint inhibitors. However, validated biomarkers to select patients for individualized precision therapy are presently lacking, resulting in high treatment failure rates, unnecessary exposure to drug toxicities, and missed treatment opportunities. Recent advances in research on the tumor and microenvironmental factors of PTCL and NKTCL, including alterations in specific molecular features and immune signatures, have improved our understanding of these diseases, though several issues continue to impede progress in clinical translation. In this Review, we summarize the progress and development of the current predictive biomarker landscape, highlight potential knowledge gaps, and discuss the implications on novel therapeutics development in PTCL and NKTCL.

Published
2023
Full Text
View/download PDF

4. DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

Author

Atish Kizhakeyil, Nurmahirah Binte Mohammed Zaini, Zhi Sheng Poh, Brandon Han Siang Wong, Xinpeng Loh, Aik Seng Ng, Zun Siong Low, Praseetha Prasannan, Chun Gong, Michelle Guet Khim Tan, Chandramouli Nagarajan, Dachuan Huang, Pang Wan Lu, Jing Quan Lim, Sharon Barrans, Choon Kiat Ong, Soon Thye Lim, Wee Joo Chng, George Follows, Daniel J. Hodson, Ming Qing Du, Yeow Tee Goh, Suat Hoon Tan, Nicholas Francis Grigoropoulos, and Navin Kumar Verma

Subjects
DDX3X mutation, Hematolymphoid malignancy, Prognosis, Tumour metastasis, Drug resistance, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2021
Full Text
View/download PDF

5. PRDM15 is a key regulator of metabolism critical to sustain B-cell lymphomagenesis

Author

Slim Mzoughi, Jia Yi Fong, David Papadopoli, Cheryl M. Koh, Laura Hulea, Paolo Pigini, Federico Di Tullio, Giuseppe Andreacchio, Michal Marek Hoppe, Heike Wollmann, Diana Low, Matias J. Caldez, Yanfen Peng, Denis Torre, Julia N. Zhao, Oro Uchenunu, Gabriele Varano, Corina-Mihaela Motofeanu, Manikandan Lakshmanan, Shun Xie Teo, Cheng Mun Wun, Giovanni Perini, Soo Yong Tan, Chee Bing Ong, Muthafar Al-Haddawi, Ravisankar Rajarethinam, Susan Swee-Shan Hue, Soon Thye Lim, Choon Kiat Ong, Dachuan Huang, Siok-Bian Ng, Emily Bernstein, Dan Hasson, Keng Boon Wee, Philipp Kaldis, Anand Jeyasekharan, David Dominguez-sola, Ivan Topisirovic, and Ernesto Guccione

Subjects
Science
Abstract

The transcriptional regulator PRDM15 is expressed at low levels in normal tissues but overexpressed in B-cell lymphomas. Here, the authors show that PRDM15 depletion does not affect adult somatic cell homeostasis but leads to a metabolic crisis which impairs B-cell lymphomagenesis.

Published
2020
Full Text
View/download PDF

6. Improving the Oxidation Stability and Shelf-Life of Peanut Oil by Addition of Rosemary Extract Combined with Vitamin C and Ascorbyl Palmitate

Author

Ying Wang, Hui Deng, Dachuan Huang, and Xianghui Zeng

Subjects
Nutrition. Foods and food supply, TX341-641
Abstract

Rosemary extracts are natural antioxidants, which can be considered an alternative for synthetic antioxidants in the food industry. The aim of the present study was to evaluate the oxidation stability and shelf-life of rosemary extracts combined with vitamin C (VC) and ascorbyl palmitate (AP) in peanut oil stored at 65°C. Peanut oil with tertbutyl hydroquinone (TBHQ) and without additives served as positive and negative controls, respectively. The peroxide value (POV), thiobarbituric acid reactant (TBARs), conjugated diene (CD), and conjugated triene (CT) values of the peanut oil samples were evaluated during accelerated storage every 48 h. Among them, 0.23 g/kg rosemary extracts combined with 0.13 g/kg VC and 0.07 mg/kg AP exhibited the best oxidative stability. Additionally, the oxidation kinetics model predicated that the rosemary extracts combined with VC and AP could effectively prolong the shelf-life of peanut oil. In accelerated storage, the rosemary extracts combined with VC and AP not only inhibited peanut oil oxidation like chemical antioxidants, but also were safer than chemical antioxidants. Therefore, the rosemary extracts combined with VC and AP were an effective alternative to chemical antioxidants, which could improve the oxidation stability and shelf-life of peanut oil.

Published
2022
Full Text
View/download PDF

7. No association between ECSIT germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma

Author

Shin Yeu Ong, Jing Quan Lim, Nicholas Grigoropoulos, Yurike Laurensia, Dachuan Huang, Burton Kuan Hui Chia, Daryl Cheah Ming Zhe, Sahil Ajit Saraf, Chee Leong Cheng, Wen-Yu Chuang, Ming-Chung Kuo, Yi-Jiun Su, Colin Phipps, Chandramouli Nagarajan, Yuh Shan Lee, Daryl Tan Chen Lung, Lee-Yung Shih, Yeow Tee Goh, Soon Thye Lim, and Choon Kiat Ong

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2020
Full Text
View/download PDF

8. Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein

Author

Laura A. Laviolette, Julien Mermoud, Isabel A. Calvo, Nicholas Olson, Myriam Boukhali, Ortrud K. Steinlein, Elisabeth Roider, Elke C. Sattler, Dachuan Huang, Bin Tean Teh, Mo Motamedi, Wilhelm Haas, and Othon Iliopoulos

Subjects
Science
Abstract

Folliculin is a known tumour suppressor but the molecular mechanisms behind this function are unclear. Here the authors show that Folliculin regulates EGFR signalling by modulating its Rab7a-dependent trafficking.

Published
2017
Full Text
View/download PDF

11. PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma

Author

Xiaosai Yao, Jing Han Hong, Amrita M. Nargund, Michelle Shu Wen Ng, Hong Lee Heng, Zhimei Li, Peiyong Guan, Masahiro Sugiura, Pek Lim Chu, Loo Chien Wang, Xiaofen Ye, James Qu, Xiu Yi Kwek, Jeffrey Chun Tatt Lim, Wen Fong Ooi, Joanna Koh, Zhenxun Wang, You-Fu Pan, Yan Shan Ong, Kiat-Yi Tan, Jian Yuan Goh, Sheng Rong Ng, Luca Pignata, Dachuan Huang, Alexander Lezhava, Su Ting Tay, Minghui Lee, Xun Hui Yeo, Wai Leong Tam, Sun Young Rha, Shang Li, Ernesto Guccione, Andrew Futreal, Jing Tan, Joe Poh Sheng Yeong, Wanjin Hong, Robert Yauch, Kenneth Tou-En Chang, Radoslaw M. Sobota, Patrick Tan, and Bin Tean Teh

Subjects
Cell Biology
Published
2023
Full Text
View/download PDF

13. A genomic‐augmented multivariate prognostic model for the survival of natural‐killer/T‐cell lymphoma patients from an international cohort

Author

Jing Quan Lim, Dachuan Huang, Jason Yongsheng Chan, Yurike Laurensia, Esther Kam Yin Wong, Daryl Ming Zhe Cheah, Burton Kuan Hui Chia, Wen‐Yu Chuang, Ming‐Chung Kuo, Yi‐Jiun Su, Qing‐qing Cai, Yanfen Feng, Huilan Rao, Li‐Na Feng, Pan‐Pan Wei, Jie‐Rong Chen, Bo‐Wei Han, Guo‐Wang Lin, Jun Cai, Yu Fang, Jing Tan, Huangming Hong, Yanhui Liu, Fen Zhang, Wenyu Li, Michelle L. M. Poon, Siok‐Bian Ng, Anand Jeyasekharan, Jeslin Chian Hung Ha, Lay Poh Khoo, Suk Teng Chin, Wan Lu Pang, Rebecca Kee, Chee Leong Cheng, Nicholas Francis Grigoropoulos, Tiffany Tang, Miriam Tao, Mohamad Farid, Kia Joo Puan, Jie Xiong, Wei‐Li Zhao, Chiea Chuen Khor, William Hwang, Won Seog Kim, Elias Campo, Patrick Tan, Bin Tean Teh, Wee‐Joo Chng, Olaf Rötzschke, Thomas Tousseyn, Hui‐Qiang Huang, Steve Rozen, Soon Thye Lim, Lee‐Yung Shih, Jin‐Xin Bei, and Choon Kiat Ong

Subjects
EXPRESSION, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Science & Technology, MUTATIONS, BLOCKADE, Genomics, GENETIC RISK, Hematology, Prognosis, Disease-Free Survival, VARIABLES, Lymphoma, Extranodal NK-T-Cell, PERIPHERAL T-CELL, Humans, BARR-VIRUS-DNA, NASAL, SMILE, Life Sciences & Biomedicine, Retrospective Studies
Abstract

With lowering costs of sequencing and genetic profiling techniques, genetic drivers can now be detected readily in tumors but current prognostic models for Natural-killer/T cell lymphoma (NKTCL) have yet to fully leverage on them for prognosticating patients. Here, we used next-generation sequencing to sequence 260 NKTCL tumors, and trained a genomic prognostic model (GPM) with the genomic mutations and survival data from this retrospective cohort of patients using LASSO Cox regression. The GPM is defined by the mutational status of 13 prognostic genes and is weakly correlated with the risk-features in International Prognostic Index (IPI), Prognostic Index for Natural-Killer cell lymphoma (PINK), and PINK-Epstein-Barr virus (PINK-E). Cox-proportional hazard multivariate regression also showed that the new GPM is independent and significant for both progression-free survival (PFS, HR: 3.73, 95% CI 2.07-6.73; p

Published
2022
Full Text
View/download PDF

14. Tables S1-S16 from VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma

Author

Patrick Tan, Bin Tean Teh, Jim R. Hughes, Gertrud Steger, Alexander Lezhava, David Lawrence Silver, Puay Hoon Tan, Kenneth Tou En Chang, Shang Li, Christopher Wai Sam Cheng, Iain Bee Huat Tan, Qiang Yu, Steven G. Rozen, Bryan C. Tan, Gary Loh, Jian Yuan Goh, James O. J. Davies, Swe Swe Myint, Chang Xu, Aditi Qamra, Tannistha Nandi, Joyce Suling Lin, Cassandra Zhengxuan He, Michelle Shu Wen Ng, Peiyong Guan, Ai Ping Lee-Lim, Jing Han Hong, Yue Ning Lam, Giovani Wijaya, Su Ting Tay, James Zhengzhong Qu, Yang Sun Chan, Manjie Xing, Dachuan Huang, Zhimei Li, Wen Fong Ooi, Joanna Koh, Kevin Junliang Lim, Jing Tan, and Xiaosai Yao

Abstract

Supplementary tables

Published
2023
Full Text
View/download PDF

15. Figure S1-9; Supplementary methods from VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma

Author

Patrick Tan, Bin Tean Teh, Jim R. Hughes, Gertrud Steger, Alexander Lezhava, David Lawrence Silver, Puay Hoon Tan, Kenneth Tou En Chang, Shang Li, Christopher Wai Sam Cheng, Iain Bee Huat Tan, Qiang Yu, Steven G. Rozen, Bryan C. Tan, Gary Loh, Jian Yuan Goh, James O. J. Davies, Swe Swe Myint, Chang Xu, Aditi Qamra, Tannistha Nandi, Joyce Suling Lin, Cassandra Zhengxuan He, Michelle Shu Wen Ng, Peiyong Guan, Ai Ping Lee-Lim, Jing Han Hong, Yue Ning Lam, Giovani Wijaya, Su Ting Tay, James Zhengzhong Qu, Yang Sun Chan, Manjie Xing, Dachuan Huang, Zhimei Li, Wen Fong Ooi, Joanna Koh, Kevin Junliang Lim, Jing Tan, and Xiaosai Yao

Abstract

Supplementary methods. Supplementary Figures 1-9

Published
2023
Full Text
View/download PDF

16. Torturing Databases for Fun and Profit.

Author

Mai Zheng, Joseph A. Tucek, Dachuan Huang, Feng Qin, Mark Lillibridge, Elizabeth S. Yang, Bill W. Zhao, and Shashank Singh 0003

Published
2014

18. Supplementary Table 3 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Author

Patrick Tan, Bin Tean Teh, Steve Rozen, Liang Kee Goh, Kyle A. Furge, Heike Grabsch, P. Andrew Futreal, Yujing Liu, Siyu Lim, Jiong Tao, Anna Gan, Karl Dykema, Lian Dee Ler, Dachuan Huang, Shen Li Zhang, Willie Yu, Ioana Cutcutache, Choon Kiat Ong, and Zhi Jiang Zang

Abstract

Supplementary Table 3 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Published
2023
Full Text
View/download PDF

20. Supplementary Table 9 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Author

Patrick Tan, Bin Tean Teh, Steve Rozen, Liang Kee Goh, Kyle A. Furge, Heike Grabsch, P. Andrew Futreal, Yujing Liu, Siyu Lim, Jiong Tao, Anna Gan, Karl Dykema, Lian Dee Ler, Dachuan Huang, Shen Li Zhang, Willie Yu, Ioana Cutcutache, Choon Kiat Ong, and Zhi Jiang Zang

Abstract

Supplementary Table 9 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 1 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Author

Patrick Tan, Bin Tean Teh, Steve Rozen, Liang Kee Goh, Kyle A. Furge, Heike Grabsch, P. Andrew Futreal, Yujing Liu, Siyu Lim, Jiong Tao, Anna Gan, Karl Dykema, Lian Dee Ler, Dachuan Huang, Shen Li Zhang, Willie Yu, Ioana Cutcutache, Choon Kiat Ong, and Zhi Jiang Zang

Abstract

Supplementary Figure 1 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Published
2023
Full Text
View/download PDF

22. Supplementary Table 8 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Author

Patrick Tan, Bin Tean Teh, Steve Rozen, Liang Kee Goh, Kyle A. Furge, Heike Grabsch, P. Andrew Futreal, Yujing Liu, Siyu Lim, Jiong Tao, Anna Gan, Karl Dykema, Lian Dee Ler, Dachuan Huang, Shen Li Zhang, Willie Yu, Ioana Cutcutache, Choon Kiat Ong, and Zhi Jiang Zang

Abstract

Supplementary Table 8 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Published
2023
Full Text
View/download PDF

24. Supplementary Table 5 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Author

Patrick Tan, Bin Tean Teh, Steve Rozen, Liang Kee Goh, Kyle A. Furge, Heike Grabsch, P. Andrew Futreal, Yujing Liu, Siyu Lim, Jiong Tao, Anna Gan, Karl Dykema, Lian Dee Ler, Dachuan Huang, Shen Li Zhang, Willie Yu, Ioana Cutcutache, Choon Kiat Ong, and Zhi Jiang Zang

Abstract

Supplementary Table 5 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 1 from Expression of the PTTG1 Oncogene Is Associated with Aggressive Clear Cell Renal Cell Carcinoma

Author

Bin Tean Teh, Kyle A. Furge, Richard J. Kahnoski, Brian Lane, John Anema, Aikseng Ooi, David Petillo, David Van't Hof, Julie Koeman, Choon Kiat Ong, Dachuan Huang, Zhongfa Zhang, and Bill Wondergem

Abstract

PDF file, 251K, Supplemental Figure S1 (a) Gene expression profiling of 131 clinical specimens for which we have staging information shows that overexpression of PTTG1 correlates with high tumor stage. (b) Association of increased PTTG1 expression with decreased probability of survival for 5-years. Dashed lines indicate 95% confidence intervals (c) Similarly, ECT2 overexpression is most prominent in high stage ccRCC tumors. (d) PTTG1 and ECT2 are coordinately overexpressed in primarily high stage tumors. (e) Cells completely deficient of ECT2 acquire a highly-branched and spindle-shaped morphology.

Published
2023
Full Text
View/download PDF

26. Supplementary Table 4 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Author

Patrick Tan, Bin Tean Teh, Steve Rozen, Liang Kee Goh, Kyle A. Furge, Heike Grabsch, P. Andrew Futreal, Yujing Liu, Siyu Lim, Jiong Tao, Anna Gan, Karl Dykema, Lian Dee Ler, Dachuan Huang, Shen Li Zhang, Willie Yu, Ioana Cutcutache, Choon Kiat Ong, and Zhi Jiang Zang

Abstract

Supplementary Table 4 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Published
2023
Full Text
View/download PDF

27. Supplementary Table 11 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Author

Patrick Tan, Bin Tean Teh, Steve Rozen, Liang Kee Goh, Kyle A. Furge, Heike Grabsch, P. Andrew Futreal, Yujing Liu, Siyu Lim, Jiong Tao, Anna Gan, Karl Dykema, Lian Dee Ler, Dachuan Huang, Shen Li Zhang, Willie Yu, Ioana Cutcutache, Choon Kiat Ong, and Zhi Jiang Zang

Abstract

Supplementary Table 11 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Published
2023
Full Text
View/download PDF

28. Supplementary Table 2 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Author

Patrick Tan, Bin Tean Teh, Steve Rozen, Liang Kee Goh, Kyle A. Furge, Heike Grabsch, P. Andrew Futreal, Yujing Liu, Siyu Lim, Jiong Tao, Anna Gan, Karl Dykema, Lian Dee Ler, Dachuan Huang, Shen Li Zhang, Willie Yu, Ioana Cutcutache, Choon Kiat Ong, and Zhi Jiang Zang

Abstract

Supplementary Table 2 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 2 from Expression of the PTTG1 Oncogene Is Associated with Aggressive Clear Cell Renal Cell Carcinoma

Author

Bin Tean Teh, Kyle A. Furge, Richard J. Kahnoski, Brian Lane, John Anema, Aikseng Ooi, David Petillo, David Van't Hof, Julie Koeman, Choon Kiat Ong, Dachuan Huang, Zhongfa Zhang, and Bill Wondergem

Abstract

PDF file, 646K, Supplemental Figure S2. (a) SiRNA targeting PTTG1 achieved complete suppression of PTTG1 expression for at least 72 hours. (b) Immunofluorescent staining revealed abundant nuclear and cytoplasmic localization of PTTG1 in 786-O cells and suppression of PTTG1 expression upon treatment with targeted siRNA. (c) A 2-dimensional colony formation assay demonstrated that PTTG1 knockdown had little effect on anchorage-dependent growth rate. Crystal violet staining and microscopic imaging of these colonies further revealed that 786-O cells exhibit no major morphological differences following PTTG1 knockdown.

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 3 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Author

Patrick Tan, Bin Tean Teh, Steve Rozen, Liang Kee Goh, Kyle A. Furge, Heike Grabsch, P. Andrew Futreal, Yujing Liu, Siyu Lim, Jiong Tao, Anna Gan, Karl Dykema, Lian Dee Ler, Dachuan Huang, Shen Li Zhang, Willie Yu, Ioana Cutcutache, Choon Kiat Ong, and Zhi Jiang Zang

Abstract

Supplementary Figure 3 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Published
2023
Full Text
View/download PDF

31. Supplementary Table 7 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Author

Patrick Tan, Bin Tean Teh, Steve Rozen, Liang Kee Goh, Kyle A. Furge, Heike Grabsch, P. Andrew Futreal, Yujing Liu, Siyu Lim, Jiong Tao, Anna Gan, Karl Dykema, Lian Dee Ler, Dachuan Huang, Shen Li Zhang, Willie Yu, Ioana Cutcutache, Choon Kiat Ong, and Zhi Jiang Zang

Abstract

Supplementary Table 7 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Published
2023
Full Text
View/download PDF

32. Supplementary Methods and Materials, Results, Legends for Tables 1-11 and Figures 1-3 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Author

Patrick Tan, Bin Tean Teh, Steve Rozen, Liang Kee Goh, Kyle A. Furge, Heike Grabsch, P. Andrew Futreal, Yujing Liu, Siyu Lim, Jiong Tao, Anna Gan, Karl Dykema, Lian Dee Ler, Dachuan Huang, Shen Li Zhang, Willie Yu, Ioana Cutcutache, Choon Kiat Ong, and Zhi Jiang Zang

Abstract

Supplementary Methods and Materials, Results, Legends for Tables 1-11 and Figures 1-3 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Published
2023
Full Text
View/download PDF

33. Supplementary Table 6 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Author

Patrick Tan, Bin Tean Teh, Steve Rozen, Liang Kee Goh, Kyle A. Furge, Heike Grabsch, P. Andrew Futreal, Yujing Liu, Siyu Lim, Jiong Tao, Anna Gan, Karl Dykema, Lian Dee Ler, Dachuan Huang, Shen Li Zhang, Willie Yu, Ioana Cutcutache, Choon Kiat Ong, and Zhi Jiang Zang

Abstract

Supplementary Table 6 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 2 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Author

Patrick Tan, Bin Tean Teh, Steve Rozen, Liang Kee Goh, Kyle A. Furge, Heike Grabsch, P. Andrew Futreal, Yujing Liu, Siyu Lim, Jiong Tao, Anna Gan, Karl Dykema, Lian Dee Ler, Dachuan Huang, Shen Li Zhang, Willie Yu, Ioana Cutcutache, Choon Kiat Ong, and Zhi Jiang Zang

Abstract

Supplementary Figure 2 from Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 3 from Expression of the PTTG1 Oncogene Is Associated with Aggressive Clear Cell Renal Cell Carcinoma

Author

Bin Tean Teh, Kyle A. Furge, Richard J. Kahnoski, Brian Lane, John Anema, Aikseng Ooi, David Petillo, David Van't Hof, Julie Koeman, Choon Kiat Ong, Dachuan Huang, Zhongfa Zhang, and Bill Wondergem

Abstract

PDF file, 278K, Supplemental Figure S3. Direct targeting of ECT2 by siRNA results in a dose-dependent inhibition of ccRCC cell growth. (a) MTS proliferation assays showed a dose-dependent reduction in 786-O cell growth upon treatment with siRNA's targeting ECT2. (b) Depletion of ECT2 results in an accumulation of cells in G2/M phase. (c) Cells unable to complete cell division acquired a multinucleate phenotype, indicative of cytokinesis defects upon ECT2 knockdown.

Published
2023
Full Text
View/download PDF

36. Supplementary Table 3 from Expression of the PTTG1 Oncogene Is Associated with Aggressive Clear Cell Renal Cell Carcinoma

Author

Bin Tean Teh, Kyle A. Furge, Richard J. Kahnoski, Brian Lane, John Anema, Aikseng Ooi, David Petillo, David Van't Hof, Julie Koeman, Choon Kiat Ong, Dachuan Huang, Zhongfa Zhang, and Bill Wondergem

Abstract

PDF file, 27K, FISH Samples: Clinical Features and Maximum PTTG1 Copy Number. Interphase FISH analysis of ccRCC tumor touch preparations. FISH probe locations are shown in Figure 1a.

Published
2023
Full Text
View/download PDF

39. CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma

Author

Jinghong Chen, Jing Tan, Shini Liu, Kelila Xin Ye Chai, Choon Kiat Ong, Hui-Qiang Huang, Daryl Ming Zhe Cheah, Soon Thye Lim, Jason Yongsheng Chan, Haixia He, Yan Teng, Jing Quan Lim, Bin Tean Teh, Wenyu Li, Jianfeng Chen, Xiaoxiao Wang, Burton Kuan Hui Chia, Nicholas Francis Grigoropoulos, Yali Wang, Qiang Yu, Jing Han Hong, Dachuan Huang, Ling Huang, Yichen Sun, Lizhen Liu, Peng Deng, Yan Gao, and Diwen Pang

Subjects
Cancer Research, biology, business.industry, Kinase, Histone acetyltransferase, Cell cycle, medicine.disease, Lymphoma, chemistry.chemical_compound, Oncology, chemistry, In vivo, Chidamide, medicine, biology.protein, Cancer research, Histone deacetylase, business, Diffuse large B-cell lymphoma
Abstract

Diffuse large B-cell lymphoma (DLBCL) exhibits frequent inactivating mutations of the histone acetyltransferase CREBBP, highlighting the attractiveness of targeting CREBBP deficiency as a therapeutic strategy. In this study, we demonstrate that chidamide, a novel histone deacetylase (HDAC) inhibitor, is effective in treating a subgroup of relapsed/refractory DLBCL patients, achieving an overall response rate (ORR) of 25.0% and a complete response (CR) rate of 15.0%. However, the clinical response to chidamide remains poor, as most patients exhibit resistance, hampering the clinical utility of the drug. Functional in vitro and in vivo studies have shown that CREBBP loss of function is correlated with chidamide sensitivity, which is associated with modulation of the cell cycle machinery. A combinatorial drug screening of 130 kinase inhibitors targeting cell cycle regulators identified AURKA inhibitors, which inhibit the G2/M transition during the cell cycle, as top candidates that synergistically enhanced the antitumor effects of chidamide in CREBBP-proficient DLBCL cells. Our study demonstrates that CREBBP inactivation can serve as a potential biomarker to predict chidamide sensitivity, while combination of an AURKA inhibitor and chidamide is a novel therapeutic strategy for the treatment of relapsed/refractory DLBCL.

Published
2021
Full Text
View/download PDF

40. An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma

Author

Jasmine Goh, Sanjay De Mel, Michal M. Hoppe, Masturah Bte Mohd Abdul Rashid, Xi Yun Zhang, Patrick Jaynes, Esther Ka Yan Ng, Nur’Atiqa Diana Binti Rahmat, null Jayalakshmi, Clementine Xin Liu, Limei Poon, Esther Chan, Joanne Lee, Yen Lin Chee, Liang Piu Koh, Lip Kun Tan, Teck Guan Soh, Yi Ching Yuen, Hoi-Yin Loi, Siok-Bian Ng, Xueying Goh, Donovan Eu, Stanley Loh, Sheldon Ng, Daryl Tan, Daryl Ming Zhe Cheah, Wan Lu Pang, Dachuan Huang, Shin Yeu Ong, Chandramouli Nagarajan, Jason Yongsheng Chan, Jeslin Chian Hung Ha, Lay Poh Khoo, Nagavalli Somasundaram, Tiffany Tang, Choon Kiat Ong, Wee-Joo Chng, Soon Thye Lim, Edward K. Chow, and Anand D. Jeyasekharan

Subjects
Drug Combinations, Lymphoma, Non-Hodgkin, Antineoplastic Combined Chemotherapy Protocols, Humans, General Medicine, Prospective Studies, Neoplasm Recurrence, Local
Abstract

Although combination therapy is the standard of care for relapsed/refractory non-Hodgkin’s lymphoma (RR-NHL), combination treatment chosen for an individual patient is empirical, and response rates remain poor in individuals with chemotherapy-resistant disease. Here, we evaluate an experimental-analytic method, quadratic phenotypic optimization platform (QPOP), for prediction of patient-specific drug combination efficacy from a limited quantity of biopsied tumor samples. In this prospective study, we enrolled 71 patients with RR-NHL (39 B cell NHL and 32 NK/T cell NHL) with a median of two prior lines of treatment, at two academic hospitals in Singapore from November 2017 to August 2021. Fresh biopsies underwent ex vivo testing using a panel of 12 drugs with known efficacy against NHL to identify effective single and combination treatments. Individualized QPOP reports were generated for 67 of 75 patient samples, with a median turnaround time of 6 days from sample collection to report generation. Doublet drug combinations containing copanlisib or romidepsin were most effective against B cell NHL and NK/T cell NHL samples, respectively. Off-label QPOP-guided therapy offered at physician discretion in the absence of standard options ( n = 17) resulted in five complete responses. Among patients with more than two prior lines of therapy, the rates of progressive disease were lower with QPOP-guided treatments than with conventional chemotherapy. Overall, this study shows that the identification of patient-specific drug combinations through ex vivo analysis was achievable for RR-NHL in a clinically applicable time frame. These data provide the basis for a prospective clinical trial evaluating ex vivo–guided combination therapy in RR-NHL.

Published
2022

43. Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma

Author

Vikneswari Rajasegaran, Chee Leong Cheng, Junhun Cho, Lay Poh Khoo, Huangming Hong, Daryl Tan, Daryl Ming Zhe Cheah, Dachuan Huang, Rou-Jun Peng, Jeslin Chian Hung Ha, Jing Quan Lim, Yeow Tee Goh, Burton Kuan Hui Chia, Seok Jin Kim, Tiffany Tang, Olaf Rötzschke, Eric Tse, Choon Kiat Ong, Won Seog Kim, Maarja-Liisa Nairismagi, Yok-Lam Kwong, Qingqing Cai, Colin Phipps, Yurike Laurensia, Jing Tan, Yvonne Loh, Jin-Xin Bei, Soon Thye Lim, Tongyu Lin, Benjamin Mow, Qi-Chun Cai, Johnathan Xiande Lim, Rex Au-Yeung, Cedric Chuan Young Ng, Esther Kam Yin Wong, Thomas S. Y. Chan, Li-Mei Poon, Jason Yongsheng Chan, Nicholas Francis Grigoropoulos, Jabed Iqbal, and William Hwang

Subjects
Whole genome sequencing, Cancer Research, biology, business.industry, Hematology, Pembrolizumab, Natural killer T cell, medicine.disease, Lymphoma, Text mining, Oncology, Refractory, Monoclonal, biology.protein, Cancer research, medicine, Antibody, business
Published
2020
Full Text
View/download PDF

44. PRDM15 is a key regulator of metabolism critical to sustain B-cell lymphomagenesis

Author

Heike Wollmann, David Papadopoli, Ravisankar Rajarethinam, Giovanni Perini, Michal Marek Hoppe, Laura Hulea, Soo Yong Tan, Emily Bernstein, Susan Swee Shan Hue, Choon Kiat Ong, Siok Bian Ng, Soon Thye Lim, Slim Mzoughi, Cheryl M. Koh, Ivan Topisirovic, Federico Di Tullio, Manikandan Lakshmanan, Corina Mihaela Motofeanu, Ernesto Guccione, Cheng Mun Wun, Oro Uchenunu, Chee Bing Ong, David Dominguez-Sola, Shun Xie Teo, Diana Low, Giuseppe Andreacchio, Gabriele Varano, Dachuan Huang, Muthafar Al-Haddawi, Paolo Pigini, Denis Torre, Y Peng, Anand D. Jeyasekharan, Julia N. Zhao, Philipp Kaldis, Jia Yi Fong, Matias J. Caldez, Keng Boon Wee, Dan Hasson, Mzoughi, Slim, Fong, Jia Yi, Papadopoli, David, Koh, Cheryl M, Hulea, Laura, Pigini, Paolo, Di Tullio, Federico, Andreacchio, Giuseppe, Hoppe, Michal Marek, Wollmann, Heike, Low, Diana, Caldez, Matias J, Peng, Yanfen, Torre, Deni, Zhao, Julia N, Uchenunu, Oro, Varano, Gabriele, Motofeanu, Corina-Mihaela, Lakshmanan, Manikandan, Teo, Shun Xie, Wun, Cheng Mun, Perini, Giovanni, Tan, Soo Yong, Ong, Chee Bing, Al-Haddawi, Muthafar, Rajarethinam, Ravisankar, Hue, Susan Swee-Shan, Lim, Soon Thye, Ong, Choon Kiat, Huang, Dachuan, Ng, Siok-Bian, Bernstein, Emily, Hasson, Dan, Wee, Keng Boon, Kaldis, Philipp, Jeyasekharan, Anand, Dominguez-Sola, David, Topisirovic, Ivan, and Guccione, Ernesto

Subjects
0301 basic medicine, Lymphoma, Transcription Factor, Somatic cell, Regulator, General Physics and Astronomy, Apoptosis, Mice, SCID, Mice, Phosphatidylinositol 3-Kinases, Random Allocation, 0302 clinical medicine, lcsh:Science, Multidisciplinary, B-cell lymphoma, Flow Cytometry, Cell biology, DNA-Binding Proteins, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, Human, Chromatin Immunoprecipitation, Cell Survival, DNA-Binding Protein, Science, Blotting, Western, Biology, Article, General Biochemistry, Genetics and Molecular Biology, NO, 03 medical and health sciences, medicine, Animals, Humans, Transcriptomics, Gene, Protein kinase B, PI3K/AKT/mTOR pathway, B cell, Animal, Apoptosi, Computational Biology, General Chemistry, medicine.disease, 030104 developmental biology, Gene Expression Regulation, lcsh:Q, Phosphatidylinositol 3-Kinase, Transcriptome, Chromatin immunoprecipitation, Transcription Factors
Abstract

PRDM (PRDI-BF1 and RIZ homology domain containing) family members are sequence-specific transcriptional regulators involved in cell identity and fate determination, often dysregulated in cancer. The PRDM15 gene is of particular interest, given its low expression in adult tissues and its overexpression in B-cell lymphomas. Despite its well characterized role in stem cell biology and during early development, the role of PRDM15 in cancer remains obscure. Herein, we demonstrate that while PRDM15 is largely dispensable for mouse adult somatic cell homeostasis in vivo, it plays a critical role in B-cell lymphomagenesis. Mechanistically, PRDM15 regulates a transcriptional program that sustains the activity of the PI3K/AKT/mTOR pathway and glycolysis in B-cell lymphomas. Abrogation of PRDM15 induces a metabolic crisis and selective death of lymphoma cells. Collectively, our data demonstrate that PRDM15 fuels the metabolic requirement of B-cell lymphomas and validate it as an attractive and previously unrecognized target in oncology., The transcriptional regulator PRDM15 is expressed at low levels in normal tissues but overexpressed in B-cell lymphomas. Here, the authors show that PRDM15 depletion does not affect adult somatic cell homeostasis but leads to a metabolic crisis which impairs B-cell lymphomagenesis.

Published
2020
Full Text
View/download PDF

45. Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma

Author

Daryl Ming Zhe Cheah, Sanjay de Mel, Masturah Bte Mohd Rashid, Jing Quan Lim, Edward Kai-Hua Chow, Choon Kiat Ong, Siok Bian Ng, Soo Yong Tan, Chun Tsu Lee, Soon Thye Lim, Joanne Lee, Wee Joo Chng, Xin Liu, Hoi-Yin Loi, Yi Ching Yuen, Tiffany Tang, Xi Yun Zhang, Li Mei Poon, Yurike Laurensia, Lip Kun Tan, Dachuan Huang, Anand D. Jeyasekharan, Esther H. L. Chan, Jasmine Goh, Esther Kam Yin Wong, Wan Lu Pang, Yen Lin Chee, and Burton Kuan Hui Chia

Subjects
Drug, business.industry, Refractory T-Cell Lymphoma, media_common.quotation_subject, Complete remission, Hematology, Translational research, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Lymphoma, Oncology, Correspondence, Cancer research, Medicine, T-cell lymphoma, business, Ex vivo, media_common
Published
2020
Full Text
View/download PDF

46. Evaluation of the PIK3 pathway in peripheral T‐cell lymphoma and NK/T‐cell lymphoma

Author

Chee Leong Cheng, Jing Quan Lim, Choon Kiat Ong, Wan-Lu Pang, Yurike Laurensia, Maarja-Liisa Nairismagi, Jing Tan, Tiffany Tang, Nagavalli Somasundaram, Giovani Giovani-Clarest Wijaya, Tammy Song, Ningshu Liu, Esther Kam Yin Wong, Burton Kuan Hui Chia, Soon Thye Lim, Jason Yongsheng Chan, Dachuan Huang, Oliver Politz, Sze Huey Tan, and Daryl Cheah Ming Zhe

Subjects
Male, copanlisib, PI3K, peripheral T‐cell lymphoma, 03 medical and health sciences, chemistry.chemical_compound, phosphatidylinositol 3‐kinase, 0302 clinical medicine, International Prognostic Index, medicine, T-cell lymphoma, PTEN, Tensin, Humans, PI3K/AKT/mTOR pathway, Copanlisib, Cell Proliferation, biology, business.industry, Lymphoma, T-Cell, Peripheral, Haematological Malignancy ‐ Clinical, Hematology, Middle Aged, medicine.disease, Peripheral T-cell lymphoma, Lymphoma, chemistry, 030220 oncology & carcinogenesis, biology.protein, Cancer research, NK/T‐cell lymphoma, Natural Killer T-Cells, Female, Phosphatidylinositol 3-Kinase, business, 030215 immunology, Research Paper
Abstract

Summary Peripheral T‐cell lymphomas (PTCL) and natural killer (NK)/T‐cell lymphomas (NKTCL) are a heterogeneous group of aggressive malignancies with dismal outcomes and limited treatment options. While the phosphatidylinositol 3‐kinase (PIK3) pathway has been shown to be highly activated in many B‐cell lymphomas, its therapeutic relevance in PTCL and NKTCL remains unclear. The aim of this study is to investigate the expression of PIK3 and phosphatase and tensin homolog (PTEN) in these subtypes of lymphoma and to identify potential therapeutic targets for clinical testing. Therefore, the expression of PIK3α, PIK3β, PIK3γ, PIK3δ and PTEN was analyzed in 88 cases of PTCL and NKTCL samples by immunohistochemistry. All PTCL and NKTCL samples demonstrated high expression of PIK3 isoforms. In particular, high PIK3α expression was significantly associated with poor survival, even after adjustment for age, International Prognostic Index (IPI) score and anthracycline‐based chemotherapy in first line. Notably, copanlisib, a pan‐class I inhibitor with predominant activities towards PIK3α and PIK3δ isoforms, effectively inhibited phosphorylation of AKT, 4E‐BP‐1 and STAT3, causing G0/G1 cell cycle arrest and resulting in suppression of tumour cell growth in vitro and in vivo. This study provides evidence that targeting the PIK3 pathway, particularly simultaneous inhibition of PIK3α and δ, could be a promising approach for the treatment of PTCL and NKTCL.

Published
2020

47. DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

Author

Navin Kumar Verma, Michelle G.K. Tan, Pang Wan Lu, Wee Joo Chng, Sharon Barrans, Praseetha Prasannan, Chandramouli Nagarajan, Aik Seng Ng, Atish Kizhakeyil, Brandon Han Siang Wong, Choon Kiat Ong, Dachuan Huang, Nicholas Francis Grigoropoulos, Chun Gong, Jing Quan Lim, George A Follows, Zhi Sheng Poh, Xinpeng Loh, Nurmahirah Binte Mohammed Zaini, Yeow Tee Goh, Daniel J. Hodson, Ming-Qing Du, Soon Thye Lim, Suat Hoon Tan, Zun Siong Low, Verma, Navin Kumar [0000-0002-5940-6633], and Apollo - University of Cambridge Repository

Subjects
STAT3 Transcription Factor, Tumour metastasis, Cancer Research, Antineoplastic Agents, Drug resistance, Aggressive Non-Hodgkin Lymphoma, Biology, Hematolymphoid malignancy, DEAD-box RNA Helicases, 03 medical and health sciences, 0302 clinical medicine, Cell Line, Tumor, Exome Sequencing, Biomarkers, Tumor, medicine, Humans, Cyclin D1, DDX3X mutation, Letter to the Editor, RC254-282, 030304 developmental biology, 0303 health sciences, Lymphoma, Non-Hodgkin, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, medicine.disease, 3. Good health, Oncology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Mutation, Disease Progression, Cancer research, Molecular Medicine, Lymphoma, Large B-Cell, Diffuse, Mitogen-Activated Protein Kinases, DDX3X, Diffuse large B-cell lymphoma
Abstract

Non-Hodgkin a diverse group of malignancies, encompassing the common difuse large B-cell lymphoma (DLBCL) to the rarer T-cell lymphomas. Chemoresistance is a major barrier to treatment and the mechanisms through which it occurs are incompletely understood [1]. Although eforts are made to target frequently dysregulated pathways in NHL subtypes, these diseases still evolve into aggressive forms resistant even to newer therapies [2].

Published
2021
Full Text
View/download PDF

48. No association between ECSIT germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma

Author

Yuh Shan Lee, Chee Leong Cheng, Yurike Laurensia, Daryl Tan Chen Lung, Jing Quan Lim, Colin Phipps, Dachuan Huang, Burton Kuan Hui Chia, Shih Ly, Yi-Jiun Su, Yeow Tee Goh, Ming-Chung Kuo, Daryl Cheah Ming Zhe, Choon Kiat Ong, Sahil Saraf, Wen-Yu Chuang, Nicholas Francis Grigoropoulos, Soon Thye Lim, Shin Yeu Ong, and Chandramouli Nagarajan

Subjects
Hemophagocytic lymphohistiocytosis, Germline mutation, Immunology, medicine, Hematology, Biology, medicine.disease, Natural killer T cell, Lymphoma
Published
2020
Full Text
View/download PDF

49. A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study

Author

Eileen Poon, Jing Tan, Lay Poh Khoo, Mohamad Farid, Seok Kim, Tiffany Tang, Daryl Ming Zhe Cheah, Tammy Song, Chee Leong Cheng, Choon Kiat Ong, Jing Quan Lim, Won Seog Kim, Leonard Tan, Dachuan Huang, Khee Ming Tan, Soon Thye Lim, Miriam Tao, Yurike Laurensia, Burton Kuan Hui Chia, Nagavalli Somasundaram, Jason Yongsheng Chan, Jane Wan Lu Pang, and Lee Kong Chian School of Medicine (LKCMedicine)

Subjects
Male, 0301 basic medicine, Neutrophils, Biopsy, lcsh:Medicine, Kaplan-Meier Estimate, Systemic inflammation, Gastroenterology, Peripheral T-cell Lymphoma (PTCL), 0302 clinical medicine, Lymphocytes, Stage (cooking), lcsh:Science, Aged, 80 and over, Multidisciplinary, Middle Aged, Prognosis, Natural killer T cell, Gene Expression Regulation, Neoplastic, Killer Cells, Natural, Lymphoma, Extranodal NK-T-Cell, Extranodal Natural Killer/T-cell Lymphoma (NKTL), Treatment Outcome, 030220 oncology & carcinogenesis, T-cell lymphoma, Female, medicine.symptom, Adult, Risk, medicine.medical_specialty, Adolescent, Sensitivity and Specificity, Article, Disease-Free Survival, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Humans, Medicine [Science], Survival analysis, Aged, Proportional Hazards Models, Inflammation, Receiver operating characteristic, business.industry, lcsh:R, Nasal type, medicine.disease, Lymphoma, 030104 developmental biology, Multicenter study, Multivariate Analysis, lcsh:Q, business
Abstract

Extranodal NK/T-cell lymphoma, nasal type (NKTL) is an aggressive type of non-Hodgkin lymphoma closely associated with Epstein-Barr virus and characterized by varying degrees of systemic inflammation. We aim to examine the prognostic significance of peripheral blood neutrophil-lymphocyte ratio (NLR) in patients with NKTL. Therefore, we conducted a retrospective review of 178 patients with biopsy-proven NKTL from the National Cancer Centre Singapore and Samsung Medical Center, South Korea. Using receiver operating curve analysis, an optimal cut-off for high NLR (>3.5) in predicting overall survival (OS) was derived. Survival analysis was performed using the Kaplan-Meier method and multivariable Cox proportional regression. In patients with high NLR, estimated 5-year OS was 25% compared to 53% in those with low NLR. In multivariable analysis, high NLR, in addition to age ≥60 years, presence of B-symptoms and stage III/IV at diagnosis, was independently correlated with worse OS (HR 2.08; 95% CI 1.36 to 3.18; p = 0.0008) and progression-free survival (HR 1.66; 95% CI 1.11 to 2.46; p = 0.0128). A new prognostic index (NABS score) derived from these factors stratified patients into low (0), low-intermediate (1), high-intermediate (2) and high (3–4) risk subgroups, which were associated with 5-year OS of 76.5%, 55.7%, 29.2% and 0% respectively. In conclusion, high NLR is an independent prognostic marker and the NABS model can be used to risk-stratify NKTL patients.

Published
2019
Full Text
View/download PDF

50. CLINICAL APPLICATION OF AN EX‐VIVO PLATFORM TO GUIDE THE CHOICE OF DRUG COMBINATIONS IN RELAPSED/REFRACTORY LYMPHOMA; A PROSPECTIVE STUDY

Author

Yi Ching Yuen, Choon Kiat Ong, S. de Mel, L. K Tan, Masturah Bte Mohd Rashid, Nagavalli Somasundaram, Tiffany Tang, Xi Yun Zhang, Hoi‐Y Loi, Jasmine Goh, Y. L Chee, Anand D. Jeyasekharan, David S.P. Tan, Dachuan Huang, Joanne Shu Xian Lee, Xin Liu, Wee Joo Chng, Edward Kai-Hua Chow, S. T Lim, Daryl Ming Zhe Cheah, Jason Yongsheng Chan, Esther Hian Li Chan, Patrick Jaynes, S.B. Ng, Li-Mei Poon, Liang Piu Koh, Wan Lu Pang, X Goh, and T. G Soh

Subjects
Oncology, Drug, Cancer Research, medicine.medical_specialty, business.industry, media_common.quotation_subject, Hematology, General Medicine, medicine.disease, Lymphoma, Internal medicine, Relapsed refractory, medicine, Prospective cohort study, business, Ex vivo, media_common
Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results